<DrugInformationSummary id="CDR0000717928"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about ruxolitinib phosphate and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinibphosphate">Ruxolitinib Phosphate</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000593437">ruxolitinib phosphate</TerminologyLink><GlossaryLink ref="CDR0000718942">ruxolitinib phosphate</GlossaryLink><USBrandNames><USBrandName>Jakafi</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>RUK-soh-LIH-tih-nib FOS-fayt</TermPronunciation><MediaLink ref="CDR0000732948" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000732947" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Ruxolitinib Phosphate</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Ruxolitinib phosphate
         is approved 
         for use in adults to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045947" dictionary="Cancer.gov" audience="Patient">myelofibrosis</GlossaryTermRef></Strong> (a <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> disease) that is intermediate risk or high risk, including the following types:<ItemizedList Style="bullet" id="_4"><ListItem><GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">primary myelofibrosis</GlossaryTermRef></ListItem><ListItem>post-<GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef> myelofibrosis</ListItem><ListItem>post-<GlossaryTermRef href="CDR0000256562" dictionary="Cancer.gov" audience="Patient">essential thrombocythemia</GlossaryTermRef> myelofibrosis</ListItem></ItemizedList></ListItem>
   
   <ListItem><Strong>polycythemia vera</Strong> in patients who cannot be treated with or have not gotten better with  <GlossaryTermRef href="CDR0000045308" dictionary="Cancer.gov" audience="Patient">hydroxyurea</GlossaryTermRef></ListItem></ItemizedList>
  <Para id="_5">Ruxolitinib phosphate
         is also being studied in the treatment of some types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Ruxolitinib Phosphate</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/593437">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a612006.html">Ruxolitinib Phosphate</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/jak-inhibitor-improves-cancer-immunotherapy">Drug Combo JAKs Up Immunotherapy in Two Clinical Trials</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C97937">Find Clinical Trials for Ruxolitinib Phosphate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2011-12-02</DateFirstPublished><DateLastModified>2024-08-08</DateLastModified></DrugInformationSummary>
